<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ RUA.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #6b7280 0%, #4b5563 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">RUA.L</div>
            <div class="company-name">RUA Life Sciences plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£8,688,438</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 460 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="color: white;">UNKNOWN</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">48</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">40</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #dbeafe; color: #1e40af;">CROWDED</span>
            </div>
            
            <div class="thesis-line">
                SELL/TAKE_PROFITS - CROWDED timing with 48/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #f0fdf4 0%, #dcfce7 100%); border: 2px solid #84cc16;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üß¨</span>
                CrashDash Intelligence ‚Ä¢ Biotech & Pharma
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#84cc16 189.36deg, #e5e7eb 189.36deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #84cc16;">53</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #84cc16; margin-bottom: 12px;">MODERATE FEAR</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üü° Cautious sentiment - assess risk/reward</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 13/40</div>
                            <div>üìâ Volume: 14/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 20/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #f59e0b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">‚ö†Ô∏è Crowded</span>
                </div>
                
                <!-- Opportunity Flag -->
                
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 90.0deg, #e5e7eb 90.0deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">25</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">‚ö™ LOW COMPRESSION (Early/Weak)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.1</strong> signals/week</div>
                                <div><strong>2</strong> RSI &lt; 20 events</div>
                                <div><strong>0</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+226%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">7/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 17.5%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.2 signals/week | 2 RSI<20 | Early stage</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 33.33333333333333%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Elevated volume - Some activity</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #eab308;">8/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #eab308; height: 100%; width: 53.333333333333336%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Moderate performer (226%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation detected</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üì∞ Negative news: 20/20 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="color: #64748b; font-size: 14px;">Limited historical data</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    ‚öñÔ∏è Mixed signals - Fear and facts balanced, wait for clarity
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Biotech & Pharma)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Clinical trial failures (Phase 1/2/3)</div><div>‚Ä¢ FDA/EMA rejection or delay</div><div>‚Ä¢ Safety concerns or adverse events</div>
                    </div>
                    <div style="margin-top: 12px; padding: 10px; background: #fef3c7; border-radius: 8px; font-size: 12px; color: #92400e; font-weight: 600;">üö® Active: Clinical trial failures (Phase 1/2/3)</div>
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Positive trial data (efficacy endpoints met)</div><div>‚Ä¢ Regulatory approvals (FDA/EMA)</div><div>‚Ä¢ Partnership deals (big pharma licensing)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Final results for period ended 30 September 2025</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Cancellation & Reissue Share Options</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Trading update</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">12 Month Interim Results</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Director/PDMR Shareholding</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #84cc16;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #84cc16; font-size: 20px;">AVOID</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    ‚ùå SELL/TAKE_PROFITS - timing CROWDED
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (2/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üü¢</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">53/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚úÖ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">CROWDED</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ö†Ô∏è</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">48/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üéØ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">40/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üß¨</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">1 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 48/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: CROWDED</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 2 rallies, 47% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 40/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Strong Technical Setup</strong><br><small>Chart quality: 10/20 ‚Ä¢ Score: 12/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 81.7% from peak ‚Ä¢ Score: 16/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Strong volume</strong><br><small>2.0x average ‚Ä¢ Score: 10/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>2 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Modest upside</strong><br><small>Historical best: +47% ‚Ä¢ Score: 5/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">47%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">47%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">1.0x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical ‚Ä¢ signal date=2024-11-08</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Active trade</div>
                    <div style="font-size: 14px; opacity: 0.9;">SELL/TAKE_PROFITS</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">1-3% position based on conviction</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Stop below recent support / invalidation level</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CROWDED timing with 48/100 APEX score. Historical data shows 2 rallies averaging 47% upside. Current position: +46.9%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Limited upside case without catalysts</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Late stage. Consider taking profits as risk/reward deteriorates.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 40/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            
            <!-- Bloomberg-style Disclaimer Box -->
            <div style="
                margin-bottom: 20px;
                padding: 16px 18px;
                background: linear-gradient(135deg, rgba(59, 130, 246, 0.05) 0%, rgba(59, 130, 246, 0.02) 100%);
                border: 1px solid rgba(59, 130, 246, 0.2);
                border-left: 3px solid #3b82f6;
                border-radius: 8px;
                font-family: 'Courier New', monospace;
                box-shadow: 0 2px 4px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: flex-start; gap: 12px;">
                    <span style="font-size: 18px; margin-top: 2px; flex-shrink: 0;">üéØ</span>
                    <div style="flex: 1;">
                        <div style="font-size: 12px; font-weight: 700; color: #1e40af; margin-bottom: 8px; letter-spacing: 0.3px;">
                            Trader-Focused Analysis:
                        </div>
                        <div style="font-size: 11px; color: #334155; line-height: 1.6; margin-bottom: 8px;">
                            Each RNS includes sentiment classification, key data extraction, and trading context. 
                            Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                        </div>
                        <div style="
                            font-size: 10px; 
                            color: #dc2626; 
                            font-weight: 600; 
                            padding: 6px 10px;
                            background: rgba(239, 68, 68, 0.08);
                            border-left: 2px solid #ef4444;
                            border-radius: 4px;
                            margin-top: 8px;
                        ">
                            ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                        </div>
                    </div>
                </div>
            </div>
            
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Final results for period ended 30 September 2025</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">POSITIVE RESULTS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Positive development - monitor for follow-through in share price.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">30th Jan 2026</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Annual Report</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">104%, 85%, 23%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
Today 07:00
RNS Number : 9991Q
RUA Life Sciences PLC
30 January 2026
RUA Life Sciences plc
("RUA Life Sciences", the "Company" or the "Group")
Final results for the period ended 30 September 2025
RUA Life Sciences, a medical device focussed CDMO specialising in implantable textile components and devices and the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM),¬†announces its audited final results for the period ended¬†30 September 2025.
Highlights
:
¬∑
Strategic objective of doubling revenue achieved with focus on growth and commercial activities.
¬∑
Revenues for 18 months ¬£6.7m (12 months to March 2024: ¬£2.2m)
¬∑
Like for like revenue growth of 104%
¬∑
¬£2.0m improvement in EBITDA to ¬£0.4m from ¬£1.6m loss.
¬∑
Loss before tax reduced 85% to ¬£0.2m (2024: ¬£2.0m)
¬∑
CDMO business strengthened with bargain purchase of ABISS (¬£0.9m gain).
¬∑
CDMO revenues ¬£5.8m (FY24 ¬£1.7m)
¬∑
23% like for like growth in RUA Biomaterials despite strength of Sterling against US dollar.
¬∑
Biomaterials revenues ¬£914,000 (FY24 ¬£496,000).
¬∑
Reduced R&D spend ¬£438,000 (2024: ¬£873,000)
¬∑
Strategy to commercialise IP created in RUA Vascular and RUA Structural Heart being pursued
¬∑
Year-end cash ¬£3,250,000 (2024: ¬£3,931,000)
Current trading and outlook
Activity levels achieved during period have continued into current year with encouraging new business pipelines.
Geoff Berg, Chairman of RUA Life Sciences, commented:
"
The two year objectives set at the time of the 2023 Strategy Review, of doubling revenues, reducing cash burn and focussing on profitability have been achieved ahead of time through strong trading and the purchase of the Abiss subsidiary in France. We look forward to building upon this success through broadening both services for current customers and expanding the customer base further
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation (2014/596), which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time.
For further information contact:
RUA Life Sciences
Tel: +44 (0)1294 317073
G Berg, Non-Executive Chairman
W Brown, Chief Executive Officer
L Smith, Group Chief Financial Officer
Cavendish Capital Markets Limited
(Nominated Advisor and Stockbroker)
Tel: +44 (0)20
7220 0500
Giles Balleny/Isaac Hooper (Corporate Finance)
Harriet Ward (Broking)
Nigel Birks (Healthcare Specialist Sales)
Michael Johnson (Sales)
About RUA Life Sciences
RUA Life Sciences plc is the ultimate parent company of the Group, whose principal activities
are the Contract Development and Manufacture of medical devices and components and exploiting the polymer and device
IP & know-how developed within the
Group.
The mission of the Group is to be a long-term trusted partner to the medical device industry through specialisation in implantable textiles and biostable polymers and related technology. This is being undertaken through:
¬∑ International growth via licensing Elast-Eon to third parties through RUA Biomaterials;
¬∑ International growth through Medical Devices and Components businesses exploiting implantable textiles expertise;
¬∑ Partnering with other parties to exploit and monetise the substantial Intellectual Property developed within the Group.
RUA Life Sciences will seek to maximise shareholder value by growing each business to achieve attractive levels of profitability or disposing of business areas if the valuations are attractive
.
A copy of this announcement will be available shortly at
www.rualifesciences.com/investor-relations/regulatory-news-alerts
.
CHAIRMAN'S STATEMENT
I am pleased to present my statement for the 18-month period to 30 September 2025. The longer reporting period results from the Company's decision to change its year-end from March to September, providing additional time to integrate the Abiss acquisition and to align our reporting cycle with that of a major customer to support improved planning. The financial results for the period to 30 September 2025 are presented below together with the strategic and organisational progress achieved by the Company. Throughout the Report and Accounts, reported revenues and expense items relate to an 18-month period, whilst prior period comparatives are for the 12 months to 31 March 2024.
Background
I concluded my statement last year by observing that RUA had recently switched from a business with funding required to finance the needs of R&D projects to a financially strong business focussed on growth, cash generation and profitability. It is against this background that we set out this report.
Trading for Year
The headline trading results demonstrate that RUA has made exceptional progress towards its objectives of growth and profitability. Revenue grew over threefold from ¬£2.19 million in the year to March 2024 to ¬£6.69 million in the 18 month period to September 2025. Losses before tax reduced from ¬£2.02 million to ¬£0.24 million a reduction of 86%.
The Abiss acquisition added customers, capability and momentum and, on completion, generated a non-recurring bargain-purchase gain of ¬£0.9m. While that item lifts the reported result, the direction of travel is clear, a larger, better-balanced business moving toward sustainable profitability.
As set out in the Strategic Report below, the improved trading is a result of growth in Contract Manufacture and the acquisition of Abiss together with tight cost control and the elimination of certain roles within the Group.
Net cash outflow excluding proceeds from share issues was much reduced from the ¬£1.49 million in the year to March 2024 to ¬£0.66 million for the 18-month period to September 2025. It is pleasing that in the final six months of the period, there was a net cash inflow from operating activities meeting the objective of reaching a position of cash generation from trading.
Cash balances at 30 September 2025 remained strong at ¬£3.25 million after having repaid a mortgage of ¬£0.11 million on the Drummond Crescent factory unit.
Industry Drivers
In the last interim report, I discussed the long-term nature of the medical device industry. The industry in many areas is dominated by large corporations which tend to be risk averse and often leave true innovation to smaller, entrepreneurial organisations but later acquire that innovation once proven.
The regulatory environment is also highly structured, both for demonstrating the necessary safety and efficacy to obtain an initial marketing authority, and also for the additional submissions required if there is a change to a device. Against this background, progress in the industry is typically slow; however, when it does occur, it can generate high value, attractive margins and strong barriers to entry, reflecting the substantial investment required to bring a product to market and sustain it.
Achieving growth as a contract manufacturer of devices or licensor of technology is long-term in nature, as it follows the market penetration of the device.
The focus on commerciality over the past two years has not only positioned RUA well to grow alongside its partners but has brought a number of early-stage contract development opportunities that engage the R&D team and have set the foundations for future manufacturing revenues.
Future Drivers
As the business has come through the transition from being R&D to commercially focussed, revenue growth will be driven by an integrated contract development and manufacturing business working closely with partners at all stages of their product lifecycles. In addition, the business owns a substantial IP portfolio in polymers, composite materials and manufacturing processes that will drive licensing and component supply opportunities.
Conclusion
The two year objectives set at the time of the 2023 Strategy Review, of doubling revenues, reducing cash burn and focussing on profitability have been achieved ahead of time through strong trading and the purchase of the Abiss subsidiary in France. We look forward to building upon this success through broadening both services for current customers and expanding the customer base further.
BUSINESS REVIEW
G
roup Performance
The Group entered the financial period with an emphasis towards growth, profitability and cash generation. This short term commercial focus represented a significant change from previous, longer term ambitions of growing infrastructure to support R&D activities to having a short term commercial focus. At the point of this transition, a number of senior roles were eliminated from the business with total annualised payroll savings of over ¬£0.6 million. The executive leadership team was restructured and empowered to deliver on the Group objectives. Reflecting upon the objectives set for the business, they were ambitious and stretching and the progress made over the past 18 months is a significant achievement by the team.
The financial performance over the period of this report has seen a substantial improvement in the position of the Group, driven by growth in customer engagement, cost control and strategic acquisitions.
As the shape and focus of the business has changed it is an opportune time to summarise what the key activities of the Group are:
¬∑
We develop components and finished devices under contract for customers.
¬∑
We manufacture devices and components for customers under long term contracts.
¬∑
We manufacture, market and distribute our own medical devices through Abiss.
¬∑
We develop medical device and component IP in house using our talented and experienced team of engineers.
¬∑
We license our IP to industry partners to enable their devices.
As mentioned in the Chairman's Statement, product development in the medical device industry can be slow but there are a number of attractions in becoming established and embedded in these development projects:
¬∑
High barriers to entry, both technical and regulatory.
¬∑
High margin potential from both device and component supply.
¬∑
Long product lifecycles: 10-20 years providing long term revenue visibility.
RUA operates in a long term industry with high value outcomes on success. Developing a new medical device or implant is a structured, multi-year process. Each phase of development is designed to ensure product safety, reliability and regulatory compliance and can typically take from five to eight years for a device to be approved. The key stages and activities in this process are:
¬∑
Phase 1 - Research and Feasibility
Early scientific research is undertaken and prototypes are developed. This can involve up to 2 years work.
¬∑
Phase 2 - Design and Development
Engineering work is undertaken to turn prototypes into finished devices and testing of those devices is performed. Again this is typically a 2 year period.
¬∑
Phase 3 - Clinical studies
Studies to ensure device safety and performance with timescales determined by the study design but typically over a one to two year period.
¬∑
Phase 4 - Regulatory dossier submission
Review and clearance activities necessary to obtain regulatory approvals.
Once approved, the device will be launched onto the market and volume manufacture is required. A succesful device can have a lifespan of 10-20 years. Any change to the device or manufacturing process can require parts of these steps to be undertaken again.
RUA is a Contract Developer and Manufacturer of medical devices and components and we need to be engaged with customers at the appropiate stage of their device lifecycle. Our marketing approach has been to partner with customers at the Design and Development stage of their projects, becoming a key part of their R&D process (and budget) and partnering to become the manufacturer of either components or finished devices once Regulatory Approval has been achieved. Additionally, we recognised that during the product marketing phase, supply chain risks appear and customers may be let down by other external suppliers. RUA is becoming recognised as a problem solver, working succesfuly with customers to avoid product shortages.
The spectacular growth we have enjoyed in our contracting business, termed Medical Devices and Components, over the past 18 months has been a result of our reputation for quality, innovation and agility, drawing customers to RUA when they have a problem that needs to be solved. The new material project announced in July 2024 and the acquisition of Abiss in September 2024 were examples of our ability to support these needs..
Importantly, RUA is now contracted on several earlier stage projects at or beyond the Design and Development stage of device lifecycles. This will ensure additional revenue from engineering services and future device or component supply.
IP Exploitation
RUA has developed a substantial IP portfolio in house with potential and opportunities to further exploit.
The areas of IP are:
¬∑
The world leading, long term implantable polyurethane - Elast-EonTM.
¬∑
Polymer processing technology to convert textile into an Elast-Eon composite - AurTexTM.
¬∑
Mechanical testing data suite on AurTex with indications for use in multiple areas.
¬∑
Polymer heart valve technology and data including AurTex and Elast-Eon as leaflet material.
¬∑
A fully designed and developed polymer coated vascular graft together with agreed FDA protocol for clinical studies.
¬∑
A technical file ready for approval on a next generation single incision mini-sling for treatment of Stress Urinary Incontinence (SUI).
¬∑
Regulatory approved mesh devices for pelvic floor disorders.
¬∑
Next generation material as alternative to mesh/tape in SUI.
Elast-Eon
The reporting period has seen a growth in our IP related revenue from ¬£0.49 million in the year to March 2024 to ¬£0.91 million in the current 18 month period. On a like for like basis this is a 24% increase year on year. This is all related to Biomaterials and the licensing of Elast-Eon. There are growth indicators within this area with good performance from established devices in the market together with customer products currently at Design/Development/Regulatory stages that can lead to growth in licence and royalty fees.
Structural Heart
Over the past 18 months, we have continued selective investment in our AurTex material and its application for heart valve leaflets. This work has been in support of a serious interest in AurTex for a specific heart valve need. The development work is showing promise, and we hope to make further progress during the current period. The Board's objective is to move future activities in this area off book whilst being able to recognise value created to date.
Vascular
No further investment is being made in this area. Some of the technology developed has enabled early stage revenues for our Contract Design and Development business with contracts for supply of crimping services and coated grafts supplied as components for further processing. It has been a disapointment that we have to date not succeeded in finding a partner to take on the regulatory burden of bringing the graft range to market.
Abiss
This business was purchased to ensure that the supply of a range of products to a major customer remained secure. Future product strategy is being discussed with the customer, and the results of those discussions will drive how certain IP within Abiss will be exploited in the future. We have been encouraged by the depth of product IP within Abiss and are seeking to build upon it for the benefit of both the Abiss business and the wider Group.
Within the IP of the Group, there are at least four product ranges or even potential businesses that can be developed. Our strategy is to find partners willing to support each project with RUA providing Contract Development and Manufacturing services for a financial return through royalties or otherwise on the provision of the initial IP.
Outlook
Last year, we set the expectation of growing Biomaterials licence income as well as engaging with customers to double the scale of our Contract Manufacturing business. We were succesful in meeting those expectations and intend to grow each of those areas further during the current year. In addition, a key focus of management will be to exploit further the considerable IP portfolio within the business.
FINANCIAL REVIEW
The focus of the period has been to grow the established businesses of Biomaterials and Contract Manufacture, which enjoy strong contractual revenue streams and generate attractive net margins. Ambitious targets were set for the Group at the start of the period, and it is positive that we have been able to perform in line with these expectations. The period under review is an extended 18 months to 30 September 2025 as a result of the change in year-end. The corresponding results for last year represent the 12 months to 31 March 2024 and, as such, are not directly comparable.
Revenue
Group revenue for the 18-month period ended 30 September 2025 was ¬£6.7 million compared to the 12 months to 31 March 2024 of ¬£2.2 million. The period benefited from strong organic growth together with the first-time contribution from the acquisition of Abiss..
Revenue by segment
¬∑
Medical Devices and ComponentsUK Operations: ¬£3.6 million (53% of Group revenue). On a like for like basis this represents 41 % growth from higher volumes and demand together with new business from new and existing customers.
EU Operations: (Abiss Group): ¬£2.2 million (33% of Group revenue). New contribution in the period, broadening the Group's revenue base and adding complementary manufacturing income.
¬∑
Biomaterials: ¬£0.9 million (14% of Group revenue). This area grew from the ¬£0.5 million reported last year representing annualised growth of 20%.Performance remained resilient, despite the stronger Sterling versus US Dollar exchange rate during parts of the period.
Overall, the revenue profile is now more diversified, with
Medical Devices and Components (UK and Abiss combined) representing c.86% of Group revenue and Biomaterials c.14%, positioning the Group for more balanced growth going into the next period.
Acquisition of Abiss
On 6th September 2024, the Group acquired 100% of the share capital of Abiss France SAS, a France-based medical device group, for cash consideration of ¬£68k.
The acquisition provides the Group with an established manufacturing and development platform in continental Europe, broadens its medical device product offering and customer base, and is expected to generate operational and commercial synergies across the Group.
A fair value adjustment to align the identified assets and liabilities of Abiss to their estimated fair values at the acquisition date, including adjustments to inventory, property, plant and equipment, intangible assets and provisions has resulted in a gain on bargain purchase of ¬£0.9 million being recognised.
General and administrative expenses
For the 18 months to 30 September 2025, general and administrative (G&A) expenses were ¬£6.5 million (12 months to 31 March 2024: ¬£3.8 million, not directly comparable due to the extended reporting period and business mix). The 2025 figure includes 13 months of the Abiss Group.
Depreciation & amortisation: ¬£0.7 million (c.10.2% of G&A) vs ¬£0.4 million in 2024 (c.9.6%).
Cost control remains a management focus. Throughout 2025, we tightened budgeting and approval processes, enhanced spend visibility, and strengthened financial controls across the Group (including Abiss). These actions improved oversight of operating costs and are intended to support a more efficient run-rate going forward.
Research and development costs
As first outlined in November 2023, the Group continued to re-prioritise resources away from pre-commercial R&D toward near-term profitability and customer delivery.For the 18 months to 30 September 2025, the Group expensed ¬£0.4 million of Research & Development costs (12 months to 31 March 2024: ¬£0.9 million). The lower spend is a consequence of our strategy to redeploy expenditure away from long term development projects.
No development costs were capitalised in the period; all amounts were expensed to the income statement as they relate primarily to early-stage development activities, where the technical feasibility, commercial viability and timing of future revenues are not yet sufficiently certain to meet the criteria for capitalisation.
Consistent with commitments made at the 2023 fundraise, we intend to reduce R&D expenditure further over the next 12 months, concentrating only on projects that demonstrably support profitable growth or are directly funded by third parties.
Share-based payment charges
The business operates share option plans for key personnel, which incurred a charge for share-based payment expenses of ¬£171,000 for the period compared to a credit of ¬£35,000 in 2024. The non-cash credit in 2024 is attributed to a writeback related to the cancellation of share option awarded to two executives who left the Group during the year to 31 March 2024.
Net finance costs
For the 18 months to 30 September 2025, the Group recorded net finance income of ¬£21,000 (12 months to 31 March 2024: net finance costs ¬£83,000)
The improvement reflects interest earned on surplus cash held in a low-risk liquidity fund during the period and the repayment of borrowings.
This figure is net of unrealised foreign exchange losses of ¬£31,000 (2024: ¬£28,000).
Losses before taxation
In the year to 31 March 2024, the Group incurred a pre tax loss of ¬£2.0m, The trading improvements and Abiss acquisition referred to above contributed to a much reduced loss of ¬£0.2m in the 18 month period to 30 September 2025. This loss includes the effect of a ¬£0.9 million non-cash gain on bargain purchase from the Abiss acquisition. Excluding this item, the underlying loss before tax was ¬£1.1 million. The periods are not directly comparable due to the move from a 12-month to an 18-month reporting period and the acquisition of Abiss during the period.
Loss per share
Basic and diluted loss per share for the period was 0.35 pence (2024: 4.29 pence).
Taxation
The Group claims research and development tax credits each year and, since it is currently loss making, elects to surrender these tax credits for a cash rebate. The amount is included within the taxation line of the consolidated income statement in respect of amounts receivable for the surrender of research and development expenditure amounting to ¬£0.4m (2024: ¬£0.9m). The Group has not recognised any tax assets in respect of trading losses arising in the current financial year or accumulated losses in previous financial years.
EBITDA
EBITDA, which includes non-cash share-based payment expenses, improved ¬£2.0million to a positive ¬£0.4 million in the period (FY24: loss ¬£1.6 million) as a result of the improvement in revenue volumes and gross margin and gain on bargain purchase from the acquisition of the Abiss Group.
Cashflow
Closing cash at 30 September was ¬£3.2 million (2024: ¬£3.9 million)
Cash preservation remains a strategic objective. Throughout the year, operating cash outflows from operations amounted to ¬£0.2 million (2024: ¬£1.3 million), reflecting the financial activities and commitments required to sustain business operations and growth initiatives.
The business invested ¬£161,000 in capital expenditure during the year (2024: ¬£55,000), Spend remained tightly controlled and focused on essential replacement and maintenance, with no significant new capital projects undertaken, reflecting our ongoing cash preservation and cost discipline strategy.
Financial position
During the year, the Group completed the acquisition of Abiss, a French medical device business, marking a significant strategic step in expanding our capabilities and market reach. Our financial position remains robust, with net assets at 30 September 2025 of ¬£7.1 million (2024: ¬£7.2 million).
Intangible assets (not including Goodwill) reduced to ¬£0.3 million (2024: ¬£0.4 million), reflecting an amortisation charge of ¬£82,000, partially offset by ¬£11,000 of intangibles acquired with the Abiss Group.
Dividends
No dividends have been proposed for the period ended 30 September 2025 (2024: ¬£nil).
STRATEGY
The mission of the Group is to be a long-term trusted partner to the medical device industry through specialisation in implantable textiles and biostable polymers and related technology. This is being undertaken through:
¬∑
International growth via licensing Elast-Eon to third parties through RUA Biomaterials;
¬∑
International growth through Medical Devices and Components businesses exploiting implantable textiles expertise;
¬∑
Partnering with other parties to exploit and monetise the substantial Intellectual Property developed within the Group.
RUA Life Sciences will seek to maximise shareholder value by growing each business to achieve attractive levels of profitability or disposing of business areas if the valuations are attractive.
Summarised consolidated income
Period ended
30 September 2024
Year ended
31 March 2024
Notes
¬£'000
¬£'000
Revenue
2
6,689
2,191
Cost of sales
(1,438)
(415)
Gross Profit
5,251
1,756
Other income
1,014
79
Administrative expenses
(6,522)
(3,792)
Operating loss
(257)
(1,937)
Net finance income / (expense)
21
(83)
Loss before taxation
(236)
(2,020)
Taxation
3
580
Loss for the period
(233)
(1,440)
Loss attributable to:
Owners of the parent
(218)
(1,440)
Non-Controlling interest
(15)
-
(233)
(1,440)
Loss per share per Ordinary Share attributable to the owners of the parent during the year
5
Basic
(0.35)
(4.29)
Diluted
(0.35)
(4.29)
Summarised consolidated statement of financial position
Period ended
30 September 2025
Year ended
31 March 2024
Notes
¬£'000
¬£'000
Assets
Non current assets
Goodwill
301
301
Other intangible assets
348
419
Property, plant and equipment
3,074
2,456
Total non current assets
3,723
3,176
Current assets
Inventories
894
112
Trade and other receivables
1,250
950
Cash and cash equivalents
3,250
3,931
Total current assets
5,394
4,993
Total assets
9,117
8,169
Equity & Liabilities
Equity
Issued capital
3,103
3,103
Share premium
13,709
13,709
Capital redemption reserve
11,840
11,840
Other reserve
(1,305)
(1,485)
Profit and loss account
(20,203)
(19,985)
Total equity attributable to equity holders of the parent
7,144
7,182
Non-controlling interests
41
-
Total Equity
7,185
7182
Liabilities
Non-current liabilities
Borrowings
-
132
Lease liabilities
560
140
Deferred tax
167
74
Other liabilities
43
87
Total non-current liabilities
770
433
Current liabilities
Borrowings
73
31
Lease liabilities
161
86
Trade and other payables
899
408
Other liabilities
29
29
Total current liabilities
1,162
554
Total liabilities
1,932
987
Total equity and liabilities
9,117
8,169
Summarised consolidated cash flow statement
Period ended
30 September 2025
Year ended
31 March 2024
¬£'000
¬£'000
Cash flows from operating activities
Group loss after tax
(233)
(1,440)
Adjustments for:
Gain on bargain purchase
(895)
-
Amortisation of intangible assets
82
51
Depreciation of property, plant and equipment
583
313
Share-based payments
171
(35)
Net finance costs
(21)
83
Tax credit in year
(3)
(580)
(Increase)/decrease in trade and other receivables
11
(362)
(Increase)/decrease in inventories
(206)
(31)
Taxation received
142
569
(Increase)/decrease in trade and other payables
176
104
Cash inflow / (outflow) generated from operations
(193)
(1,328)
Cash flows from investing activities
Purchase of property plant and equipment
(161)
(55)
Proceeds from disposal of tangible assets
4
Acquisition of subsidiary (net of cash acquired)
98
Interest paid
(77)
25
Interest received
133
(55)
Net cash inflow / (outflow) from operating activities
(3)
(85)
Cash flows from financing activities
Proceeds from borrowing
49
7
Repayment of borrowings and leasing liabilities
(508)
(93)
Proceeds from share issue
-
3,974
Net cash inflow / (outflow) from financing activities
(459)
3,888
Net (decrease)/increase in cash and cash equivalents
(655)
2,475
Cash and cash equivalents at beginning of Period
3,931
1,484
Effect of foreign exchange rate changes
(
26
)
(28)
Cash and cash equivalents at the end of the period
3,
250
3,931
Summarised consolidated statement of changes in equity
Issued Share capital
Share Premium
Capital Redemption Reserve
Other Reserves
Non- Controlling Interest
Profit and loss account
Total equity
¬£'000
¬£'000
¬£'000
¬£'000
¬£'000
¬£'000
¬£'000
Balance at 1 April 2023
1,109
11,729
11,840
(1,450)
-
(18,545)
4,683
Shares Issued (Net of Expenses)
1,994
1,980
-
-
-
-
3,974
Share based payments
-
-
-
(35)
-
-
(35)
Transactions with owners
1,994
1,980
-
(35)
-
-
3,939
Total comprehensive loss for the period
-
-
-
-
-
(1,440)
(1,440)
Balance at 31 March 2024
3,103
13,709
11,840
(1,485)
-
(19,985)
7,182
Share based payments
-
-
-
171
-
-
171
Transactions with owners
-
-
-
171
-
-
171
Adjustment to NCI from foreign entity acquisition
-
-
-
-
56
-
56
Total comprehensive income/(loss) for the period
-
-
-
9
(15)
(218)
(224)
Balance at 30 September 2025
3,103
13,709
11,840
(1,305)
41
(20,203)
7,185
NOTES TO THE EXTRACTS FROM THE CONSOLIDATED FINANCIAL STATEMENTS
General Information
RUA Life Sciences plc (the Company) is a company incorporated and domiciled in the UK. The registered head office is 2 Drummond Crescent, Riverside Business Park, Irvine, Ayrshire, KA11 5AN.
The Company (together with its subsidiaries, the "Group") was under the control of the directors throughout the period covered in the financial statements. The list of the subsidiaries consolidated in the financial statements is shown in Note xx.
The principal activity of the Group is exploiting the value of its IP & know-how, medical device contract manufacturing and development of cardiovascular devices.
1.
Basis of preparation and status of financial information
The financial information set out in this preliminary announcement does not constitute statutory accounts as defined by section 434 of the Companies Act 2006.
The financial information for the period ended 30 September 2025 and the year ended 31 March 2024 does not constitute the Company's statutory accounts for those years. Statutory accounts for the year ended 31 March 2024 have been delivered to the Registrar of Companies. The statutory accounts for the period ended 30 September 2025 were approved by the Board on 10 November 2025 and will be delivered to the Registrar of Companies in due course. The statutory accounts for the period ended 30 September 2025 will be posted to shareholders at least 21 days before the Annual General Meeting and made available on the Group's website.
The Group's statutory financial statements for the year ended 30 September 2025, from which the financial information presented in this announcement has been extracted, were prepared in accordance with UK adopted international accounting standards ("IFRS"). The financial statements have been prepared on the historical cost basis with the exception of certain items, which are measured at fair value as disclosed in the principal accounting policies set out in the Group's Annual Report. These policies have been consistently applied to all years presented.
The preparation of financial statements in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of the amount, event, or actions, actual results may ultimately differ from these estimates.
The auditor's reports on the accounts for 30 September 2025 and 31 March 2024 were unqualified and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.
2.
Significant accounting policies - Going concern
At 30 September 2025, the Group had cash and cash equivalents of ¬£3.25 million. As at the date of approval of these financial statements, the Group's cash and cash equivalents were approximately ¬£2.8 million
The Directors have prepared detailed financial forecasts and cash flows looking beyond 12 months from the date of the approval of these financial statements. In developing these forecasts, the Directors have made assumptions based upon their view of the current and future economic conditions that will prevail over the forecast period.
The cash flow predictions are based on a period of closely controlled cash flows to maintain ongoing development at a level commensurate with our means. Third party sources of funding are being explored to accelerate the development of our vascular graft portfolio and structural heart technology, in line with our corporate objectives.
The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the planned level of activities to continue in operational existence for the foreseeable future (being a period of at least 12 months from the date of this report), and for this reason, the financial statements have been prepared on a going concern basis.
3. Revenue
Group revenue for the period was ¬£6.7 million (2024: ¬£2.2 million). The current period covers an 18-month reporting period, compared with a 12-month comparative period, and therefore, the results are not directly comparable. In addition, the increase in revenue reflects the inclusion of revenue from businesses acquired during the period. On a like-for-like basis, excluding the impact of the extended reporting period and acquisitions, underlying revenue performance was broadly in line with management expectations.
Revenue analysed by class of business
Period ended
Year ended
30 September 2025
31 March 2024
¬£'000
¬£'000
Contract Design & Manufacture of Medical Devices
5,775
1,695
Royalty revenue
914
496
Total
6,689
2,191
Revenue analysed by geographical market
Period ended
Year ended
30 September 2025
31 March 2024
¬£'000
¬£'000
Europe
1,173
196
North America
5,396
1,945
Middle East
81
50
Asia Pacific
37
-
Africa
2
-
Total
6,689
2,191
4. Other income
Other income for the period includes a gain on bargain purchase arising on the acquisition of Abiss France SAS, reflecting the excess of the fair value of the identifiable net assets acquired over the consideration transferred. The gain arose due to the distressed circumstances of the vendor following the insolvency of its ultimate parent company.
Period ended
Year ended
30 September 2025
31 March 2024
¬£'000
¬£'000
Government Grants
44
63
Rental Income
28
13
Gain On Bargain Purchase
895
-
Miscellaneous Income
47
3
Total
1,014
79
5. Acquisitions
On 6 September 2024, the Group acquired 100% of Abiss France SAS for cash consideration of ¬£68k and, through this acquisition, obtained indirect control of Abiss Poland sp. z o.o., in which Abiss France holds a 60% interest. A non-controlling interest was recognised in respect of the remaining 40% held by minority shareholders.
The acquisition resulted in a gain on bargain purchase, reflecting the distressed circumstances of the vendor following the insolvency of Abiss France's ultimate parent company. The transaction price was further influenced by the business's reliance on a single major customer and the limited pool of potential acquirers. The Group's existing technical capability, regulatory expertise and established customer relationship enabled it to complete the acquisition at a price below the fair value of the identifiable net assets acquired.
From the acquisition date to 30 September 2025, Abiss contributed revenue of ¬£2.2m and a loss before tax of ¬£0.2m to the Group. Had the acquisition occurred on 1 April 2024, Group revenue for the 18-month period would have been ¬£7.6m with a loss before tax of ¬£0.6m. Fair value adjustments reflect the alignment of acquired assets and liabilities to their estimated fair values at the acquisition date.
6.
Preliminary announcement
The summary accounts set out above do not constitute statutory accounts as defined by section 434 of the UK Companies Act 2006. The summarised consolidated statement of financial position at¬†30 September 2025, the summarised consolidated income statement, the summarised consolidated cash flow statement and the summarised consolidated statement of changes in equity for the period then ended have been extracted from the Group's statutory financial statements for the year ended¬†30 September 2025¬†upon which the auditor's opinion is unqualified and did not contain a statement under either sections 498(2) or 498(3) of the Companies Act 2006. The audit report for the year ended¬†30 September 2025¬†did not contain statements under sections 498(2) or 498(3) of the Companies Act 2006. The statutory financial statements for the year ended¬†31 March 2024¬†have been delivered to the Registrar of Companies. The¬†30 September 2025 accounts were approved by the Directors on
29 January 2026, but have not yet been delivered to the Registrar of Companies.
7.
Earnings per share
The basic and diluted loss per ordinary share of¬†0.35 pence¬†(2024: loss of¬†4.29 pence) is calculated on the loss of the Group of¬†¬£218,000¬†(2024: loss of¬†¬£1,440,000¬†) and on
62,060,272
(2024:
33,546,577
)¬†ordinary shares, being the weighted average number of shares in issue during the year.
8. Interest in subsidiary undertakings
Name of undertaking
Country of registration or incorporation
Registered office
Description of shares held
Proportion of nominal value of direct shares held
%
(i)
RUA Biomaterials Limited
Scotland
2 Drummond Crescent, Irvine, Ayrshire, KA11 5AN
Ordinary ¬£1
100
(ii)
RUA Structural Heart Limited
Scotland
2 Drummond Crescent, Irvine, Ayrshire, KA11 5AN
Ordinary ¬£1
100
(iii)
RUA Vascular Limited
Scotland
2 Drummond Crescent, Irvine, Ayrshire, KA11 5AN
Ordinary ¬£1
100
(iv)
RUA Medical Devices Limited
Scotland
2 Drummond Crescent, Irvine, Ayrshire, KA11 5AN
Ordinary ¬£1
100
(v)
Aortech International Limited
Scotland
2 Drummond Crescent, Irvine, Ayrshire, KA11 5AN
Ordinary ¬£1
100
(iv)
Analytic Biosurgical Solutions SAS
France
14 Rue de la T√©l√©matique, 42000 Saint-√âtienne, France
Ordinary ‚Ç¨1
100
(vi)
Abiss Poland Sp. z o.o
Poland
Ul.Bagrowa 1, 30-733 Krak√≥w,
Poland
Ordinary z≈Ç50
60
Posting and availability of accounts
The annual report and accounts for the period ended¬†30 September 2025¬†will be sent by post or electronically to all registered shareholders at least 21 days prior to the Annual General Meeting. Additional copies will be available for a month thereafter from the Company's office, 2 Drummond Crescent,¬†Riverside Business Park, Irvine, Ayrshire KA11 5AN. Alternatively, the document may be viewed on, or downloaded from, the Company's website:
www.rualifesciences.com
.
Notice of Annual General Meeting
Notice of the twenty-seventh Annual General Meeting of¬†RUA Life Sciences plc¬†will be posted with the Annual Report and Accounts and will be held at Gailes Hotel, Marine Drive, Irvine, Ayrshire KA11 5AE on Tuesday,¬†17 March 2026¬†at¬†11:00am.
FORMAT OF THE AGM
The AGM will be a physical meeting. The Board encourages all shareholders who are unable to, or do not wish to, attend the AGM in person to vote by proxy.
If you wish to attend the AGM in person, it would assist the Company's planning if you could please notify the Company in advance by email to lachlan.smith@rualifesciences.com, including your name as shown on the Company's Register of Members.
Any changes to these arrangements will be published on the Company's website as soon as possible before the date of the meeting and will also be circulated via a Regulatory Information Service.
Further details of the AGM will be included in the Annual Report and will published on the Company's website at
www.rualifesciences.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
FR VKLFLQFLEBBQ
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Cancellation & Reissue Share Options</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">10th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">2:55 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Cavendish Capital</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">9%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
10 Dec 2025 14:55
RNS Number : 0622L
RUA Life Sciences PLC
10 December 2025
10 December 2025
RUA Life Sciences Plc
("
RUA Life Sciences
", the "
Company
" or the "
Group
")
Cancellation & Reissue Share Options, PDMR Notice
RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon‚Ñ¢), announces that it has today cancelled, for nil consideration, certain options previously granted on 19 June 2024.
An administrative oversight following grant resulted in such options failing to be registered for EMI. The board have therefore agreed to rectify this through the cancellation and re-grant, to put the employees in no worse position than they would have been.
An equivalent number of new options have therefore been granted over ordinary shares of 5 pence each in the Company ("Options") under the Enterprise Management Incentive (EMI) share option scheme. The number, exercise price and the vesting terms and conditions of the new Options are the same as the options cancelled.
A total of 2,900,000 EMI Options have been granted, allocated as follows:
Name
Options cancelled (19 June 2024 Grant)
Options Granted (re-Grant)
Plan
Exercise price
William Brown
1,400,000
1,400,000
EMI
11 pence
Lachlan Smith
1,200,000
1,200,000
EMI
11 pence
Other employees
300,000
300,000
EMI
11 pence
Vesting and exercise
¬∑
Options vest on 19 June 2027 (three years after original grant) and are exercisable up to the plan long-stop (10 years from original grant).
¬∑
In the event of an offer to acquire the whole company prior to the plan long-stop date, vesting may accelerate in accordance with plan rules.
¬∑
If a return of capital is proposed at an amount per share that is greater than the exercise price per share of these options, they will vest immediately prior to such return of capital to allow option holders to participate.
Following the cancelation and issuance of these share options, the Company had and will continue to have 5,625,603 shares under option being 9 % of the issued share capital of the Company.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman
Lachlan Smith, CFO
Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Giles Balleny/Isaac Hooper (Corporate Finance)
Harriet Ward (Broking)
Nigel Birks (Healthcare Specialist Sales)
Michael Johnson (Sales)
Tel: +44 (0)20 7220 0500
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
1. William Brown
2. Lachlan Smith
2
Reason for the notification
a)
Position/status
1. Chief Executive Officer
2. Chief Financial Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Rua Life Sciences
Plc
b)
LEI
213800BMVB22PVOJ9Z28
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Options over Ordinary Shares of ¬£0.05 each
Identification code
ISIN: GB0033360586
b)
Nature of the transaction
Grant and cancellation of options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1.
¬£0.11 (Grant)
1,400,000
¬£0.11 (Cancellation)
1,400,000
2.
¬£0.11 (Grant)
1,200,000
¬£0.11 (Cancellation)
1,200,000
d)
Aggregated information
- Aggregated volume
N/A
- Price
N/A
e)
Date of the transaction
10 December 2025
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
DSHFFFFLSEISEIE
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Trading update</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4th Nov 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Cavendish Capital</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">80%, 105%, 95%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
4 Nov 2025 07:00
RNS Number : 9986F
RUA Life Sciences PLC
04 November 2025
RUA Life Sciences plc
("RUA Life Sciences", the "Company" or the "Group")
Trading update for the 18-month period to¬†30 September 2025
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon
TM
), is pleased to announce a trading update for the eighteen-month period ended 30 September 2025¬†("FY 2025" or "the Period"). This extended reporting period is a result of the previously reported decision to extend the Company's financial year end from 31 March to 30 September.
Trading update
Over the period, the Group has made substantial progress in growing from a Research and Development-focused business to a mature revenue-generating business, as demonstrated by the very encouraging results below.
Revenue
The Group expects to report revenues for the 18-month period of ¬£6.6 million compared to the ¬£2.2 million reported for 12 months to March 2024. Adjusting for the extended reporting period, revenues were ¬£4.4 million on a pro-rata basis and ¬£5.1 million for the final 12 months of the period.
This strong increase in revenue has been driven by a switch in focus from R&D activities to commercial activity. The key contributors were:
¬∑
Biomaterials royalties - increased from ¬£0.5 million for the 12 months to March 2024 to ¬£0.9 million for the 18 months to September 2025, representing total growth of 80%.
¬∑
UK-based Contract Manufacturing business grew revenues from ¬£1.7 million in the 12 months to March 2024 to ¬£3.5 million in the 18 months to September 2025, representing total growth of 105%.
¬∑
Abiss group, the French based medical device manufacturer acquired by the Group in September 2024 generated revenues of ¬£2.2 million in the 12 months to September 2025.
Customer Concentration
The UK based Contract Manufacture business (UKCM) historically generated around 95% of its revenue from one major customer. Substantial efforts have been made to seek to grow and diversify the customer base by numbers and value. In the final six months of the reporting period, customer concentration was reduced with 54% from the largest customer, 33% from the new supply contract announced in January this year and 13% from business development activity that if projects are successful could drive the revenue growth of the future.
Path to profitability
In 12 months to March 2024, the group sustained an operating loss of ¬£1.9 million and EBITDA loss of ¬£1.6m (adjusted for non-cash share based payments). An objective of management at the start of the period was to get the Group to breakeven and through to profitability in as short a period as possible.
At the second Interim period for the 12 months to March 2025, adjusted EBITDA of ¬£0.5 million profit was reported after benefiting from the ¬£0.9 million bargain purchase gain on the Abiss acquisition. It is anticipated that when taken for the full 18 month period to September 2025 the Group will continue to be EBITDA positive.
Cash control
In the year to March 2024, cash utilisation within the Group amounted to ¬£1.5 million, reflecting the EBITDA loss for that period. As previously reported, cash utilisation for the 12 months to March 2025 was substantially reduced to around ¬£400k with period end cash balances of ¬£3.5 million. The Group expects to report cash at 30 September 2025 of ¬£3.2 million however the net cash reduction is expected to be represented by increased working capital requirements as a result of the growth in scale of the Group.
Reporting timetable
Following the change of accounting reference date announced on¬†30 October 2024, publication of full audited accounts for the 18-month period ending¬†30 September 2025 is expected¬†by end of¬†January 2026.
Bill Brown, CEO of¬†RUA Life Sciences, stated:
"The growth achieved by RUA over the past 18 months has been exceptional demonstrated both by the revenues reported and by the ever growing opportunities with existing and new customers. This has been a true team effort and I am very grateful to everyone within the RUA Group for their contribution."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the¬†UK¬†version of the EU Market Abuse Regulation (2014/596), which is part of¬†UK¬†law by virtue of the¬†European Union¬†(Withdrawal) Act 2018, as amended and supplemented from time to time.
For further information contact:
RUA Life Sciences
Bill Brown, Chief Executive Tel: +44 (0)1294 317073
Lachlan Smith, Group¬†Chief Financial Officer
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Tel: +44 (0)20 7220 0500
Giles Balleny/Isaac Hooper (Corporate Finance)
Harriet Ward (Broking)
Nigel Birks (Healthcare Specialist Sales)
Michael Johnson (Sales)
About RUA Life Sciences
RUA Life Sciences plc¬†is the ultimate parent company of the Group, whose principal activities comprise exploiting the value
of its IP & know-how, medical device contract manufacturing and development of medical devices.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
TSTFSUFWDEISEEF
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">12 Month Interim Results</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">POSITIVE RESULTS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Positive development - monitor for follow-through in share price.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">25th Jun 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Annual Report</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">88%, 29%, 77%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
25 Jun 2025 07:00
RNS Number : 2627O
RUA Life Sciences PLC
25 June 2025
25 June 2025
RUA Life Sciences plc
("RUA Life Sciences", the "Company" or the "Group")
Interim Results
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), today announces its unaudited second interim results for the twelve months ended 31 March 2025
Highlights:
¬∑
Break even achieved with ¬£1k post tax profit (FY2024, ¬£1,440k loss)
¬∑
Revenue increased 88% to¬†¬£4,113k¬†(FY2024:¬†¬£2,191k), 29% before the consolidation of ABISS revenue from acquisition on 6 September 2024
¬∑
Strong Gross profit margin of 77% (FY2024:¬†81%)
¬∑
Strategic purchase of Abiss -¬†¬£985k¬†of net assets purchased for¬†¬£68k
¬∑
Cash burn over the twelve-month period significantly reduced
¬∑
Cash balance¬†¬£3,567k¬†(31 March 2024:¬†¬£3,931k)
Geoff Berg
,
Chairman of
RUA Life Sciences
,
commented
:
"Compared to other industries, growing a medical device business can be frustratingly slow due to the necessary regulatory requirements; however, the past 12 months have been exceptional, with a doubling in the scale of the business. The new business opportunities being pursued are equally exciting and, if successful, will add further to the growing high-quality revenues."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the¬†UK¬†version of the EU Market Abuse Regulation (2014/596), which is part of¬†UK¬†law by virtue of the¬†European Union¬†(Withdrawal) Act 2018, as amended and supplemented from time to time.
For further information contact:
RUA Life Sciences
Tel: +44 (0)1294 317073
Geoffrey Berg, Non-Executive Chairman
Bill Brown, Chief Executive
Lachlan Smith, Group Chief Financial Officer
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Tel: +44 (0)20 7220 0500
Giles Balleny/Isaac Hooper (Corporate Finance)
Jamie Anderson (Broking)
Michael Johnson (Sales)
About RUA Life Sciences
RUA Life Sciences plc is the ultimate parent company of the Group, whose principal activities comprise exploiting the value
of its IP & know-how, medical device contract manufacturing and development of medical devices.
CHAIRMAN'S STATEMENT
I am pleased to present the second interim statement covering the 12 month period to 31 March 2025. As previously announced to shareholders, the Company extended its reporting period to 30 September 2025, and the full 18 month period report and accounts will be published during January 2026. These interim accounts do, however, cover a year's trading at RUA and, compared to the previous year-end results, demonstrate the substantial progress made during the year.
The focus of the business over the past twelve months has been to increase the size and scale of our medical device and component manufacturing business whilst keeping a tight control over costs. Growing a medical device business in the short term is not straightforward as customer decisions and timelines are driven by strict regulatory considerations rather than shorter term financial objectives. Although frustrating compared to other industries, the compensation tends to be the attractive margins achievable and the longer term nature of supply contracts.
Against this general industry background, the results are encouraging.
Revenue
In the year to 31 March 2025, Group revenues grew by 88% from ¬£2,191k to ¬£4,113k, achieving much of our 2-3 year objective to double revenues within the period. All of the revenue-generating business units have contributed to this growth, with Biomaterials growing 18% from ¬£496k to ¬£587k, the Medical Device and Components business increasing 110% from ¬£1,679k to ¬£3,526k. Of this growth, ¬£550k (33%) was contributed by the UK Contract Manufacture business. On 6 September 2024, the Group acquired the business of ABISS France, and in the period from the acquisition to 31 March 2025, contributed further revenue of ¬£1,296k.
Gross Profit
Over the period, gross profits increased by 79% from ¬£1,776k to ¬£3,172k. The Gross Margin, however, fell from 81% to 77% over the period. This reduction is partly due to the Biomaterials business, on which gross margins remain at over 94%, being diluted by the faster-growing contract manufacturing business. The margins were also depressed by the integration of ABISS Group. The underlying margin in both the Biomaterials and UK Contract manufacture business increased during the period, but the Gross Margin recognised at ABISS during the period was a lower 68% reflecting on consolidation the fair value of work in progress held on the date of acquisition. The normal gross margin at ABISS has historically been around 75% and is expected to return to those levels in the medium term.
Other Income
Other income is represented in the main by the bargain purchase gain on the acquisition of ABISS. Having concluded the fair value calculation of the assets and liabilities of ABISS, the gain amounts to ¬£917k. Of this gain ¬£322k reflects the recognition of the work in progress, the attributed value of which had the resultant depressing impact on gross margin recognised on consolidation.
Costs
A key objective is to control the costs within the business. Over the period, administration costs increased by 10% to ¬£4,161. This increase is represented by the overheads within the acquired ABISS business of ¬£757k and savings made within the UK business as a result of an organisational restructure enabling higher levels of activity and efficiency.
Break-even for the period
As a result of tight cost control, growth in revenues and the initial benefits of the ABISS acquisition, a small post-tax profit of ¬£1k was achieved compared to a loss of ¬£1,440k in the comparative 12 month period.
Cash
Over the 12 months to March, the business saw consolidated cash balances reduce from ¬£3.9m to ¬£3.6m, representing cash consumption of ¬£0.3m. This reduced level of cash burn demonstrates improved cost control, and management is committed to further reducing cash burn over the remaining six months of the financial period to September 2025.
Acquisition of ABISS
On acquisition, RUA paid ¬£68k for the entire issued share capital of ABISS (France), together with a 60% interest in ABISS (Poland), a distributor of ABISS-manufactured medical devices. The (preliminary) fair value of the identified net assets on acquisition has been adjusted to ¬£985k, resulting in a bargain purchase gain of ¬£917k.
ABISS is the legal manufacturer of pelvic floor repair devices under CE Mark and a subcontract manufacturer of the same devices for a US manufacturer. ABISS was purchased with a short-term order backlog, which was fulfilled in the period. However overall, inventory levels at ABISS's customer had been increased to levels higher than required due to the supply chain risk as a result of the status of the former parent of ABISS. There will be a period of reduced orders as this excess inventory is worked through the system. However, ABISS is not anticipated to be a drag on the Group during this period.
There are
structural changes in the competitive landscape
within the
European pelvic floor device
market, driven by two of the market's major players. One has withdrawn entirely from the European market, while another has transferred its product portfolio to a business with no current European presence. The structural impact is believed to affect around 70% of an estimated market of more than ‚Ç¨25 million. These products will still require to be sourced by hospitals. ABISS 's customers should benefit from this opportunity, but ABISS is also seeking to expand its distribution networks for its own product range. ABISS has manufacturing capacity to supply a significantly larger market share, and as an indication of the operational gearing within the business, it has historically achieved a 30% net margin on revenues of over ‚Ç¨3 million.
Business review
Since the equity fund raise in December 2023, significant progress has been made by the business in its objectives of growing the contract manufacturing business and controlling costs. The progress and potential have been accelerated through the purchase of ABISS and deepening relationships with major customers allowing a shorter pathway to profitability. Over the same period, little of the progress made by the Company has been reflected in the share price, and indeed it has not progressed from the heavily discounted price of the fund raise.
The business had previously been pursuing a strategy of developing its own devices to bring to market, however, the ability to exploit these business areas was prohibited by the quantity of capital and the cost of that capital. The strategy was therefore switched to focus on the biomaterials and contract manufacturing part of the business.
We believe that the historical investment in both grafts and heart valve material will result in revenues to the group through a combination of licensing income and device/component manufacturing revenues. It is however counterproductive to have market expectations based on the potential to exploit IP at a time when the Company is marketing and negotiating potential contracts. Rather than provide a commentary of developments, we will focus on reporting the outcomes of deals once completed.
Focus for growth
RUA has been profitable on an occasional monthly basis over the period and is much closer to our objectives of being profitable on a sustainable basis. The opportunities for growth identified and being actively pursued are:
¬∑
Biomaterials
o
Continuation of organic growth from existing licensees.
o
Additional growth opportunities from signing new license agreements in new fields of use.
¬∑
Medical Devices and Components
o
Increase the customer base for Contract Manufacture development projects, leading to long-term supply contracts.
o
Deepen the relationship with existing customers by supplying more of their supply chain needs for current products.
o
Introduce existing customers to RUA IP and technology to help develop next-generation devices.
o
Increase market penetration of ABISS-manufactured devices through both existing and new sales channels.
¬∑
Structural Heart and Vascular
o
Increase IP and royalty revenue from licensing RUA-developed technology (graft and heart valve).
As mentioned at the beginning of my report, compared to other industries, growing a medical device business can be frustratingly slow due to the necessary regulatory requirements; however, the past 12 months have been exceptional, with a doubling in the scale of the business. The new business opportunities being pursued are equally exciting and, if successful, will add further to the growing high-quality revenues.
Geoff Berg, Chairman24 June 2025
CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS
Unaudited
Audited
Note
Twelve months to 31 Mar 2025
GB¬£000
Twelve months to 31 Mar 2024
GB¬£000
Revenue
3
4,113
2,191
Cost of sales
(941)
(415)
Gross profit
3,172
1,776
Other income
4
969
79
Administrative expenses
(4,161)
(3,792)
Operating Profit / (loss)
(20)
(1,937)
Net finance income / (expense)
10
(83)
Loss before taxation
(10)
(2,020)
Taxation received / (charge)
11
580
Profit / (Loss) for the period
1
(1,440)
Other comprehensive income:
Currency translation differences
-
-
Total comprehensive income for the period
1
(1,440)
Total comprehensive income for the period is attributable to:
Equity holders of the parent
6
(1,440)
Non-controlling interests
(5)
-
1
(1,440)
Profit/(Loss) per share
:
Basic & Diluted (GB Pence per share)
-
(4.29)
CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION
Unaudited
Audited
Note
31 Mar 2025
GB¬£000
31 Mar 2024
GB¬£000
Assets
Non-current assets
Goodwill
5
301
301
Other intangible assets
6
375
419
Property, plant and equipment
7
3,166
2,456
Total non-currents assets
3,842
3,176
Current assets
Inventories
8
754
112
Trade and other receivables
9
1,092
950
Cash and cash equivalents
10
3,567
3,931
Total current assets
5,413
4,993
Total assets
9,255
8,169
Equity
Issued capital
3,103
3,103
Share premium
13,709
13,709
Capital redemption reserve
11,840
11,840
Reserves
(1,375)
(1,485)
Profit and loss account
(19,979)
(19,985)
Total equity attributable to equity holders of the parent company
7,298
7,182
Non-controlling interests
94
-
Total Equity
7,392
7,182
Liabilities
Non-current liabilities
Borrowings
11
19
132
Lease liabilities
11
620
140
Deferred tax
64
74
Other Liabilities
12
58
87
Total non-current liabilities
761
433
Current liabilities
Borrowings
11
234
31
Lease liabilities
11
156
86
Trade and other payables
12
683
408
Other liabilities
12
29
29
Total current liabilities
1,102
554
Total liabilities
1,863
987
Total equity and liabilities
9,255
8,169
CONDENSED INTERIM CONSOLIDATED CASH FLOW STATEMENT
Unaudited
Audited
Twelve months to
Twelve months to
31 March 2025
31 March 2024
GB¬£000
GB¬£000
Cash flows from operating activities:
Group Profit / (Loss) after tax
1
(1,440)
Adjustments for:
Gain on bargain purchase
(917)
-
Amortisation of intangible assets
55
51
Depreciation of property, plant and equipment
366
313
Share-based payments
110
(35)
Net finance costs
(10)
83
Tax credit in year
-
(580)
(Increase)/decrease in trade and other receivables
180
(362)
(Increase)/decrease in inventories
2
(31)
Taxation received
(11)
569
(Increase)/decrease in trade and other payables
5
104
Net cash flow from operating activities
(219)
(1,328)
Cash flows from investing activities:
Purchase of property plant and equipment
(62)
(55)
Proceeds from disposal of tangible assets
1
25
Acquisition of subsidiary (net of cash acquired)
102
-
Interest paid
(51)
(55)
Interest received
80
-
Net cash flow from investing activities
70
(85)
Cash flows from financing activities:
Proceeds from borrowing
27
7
Repayment of borrowings and leasing liabilities
(223)
(93)
Proceeds from share issue
-
3,974
Net cash flow from financing activities
(196)
3,888
Net increase / (decrease) in cash and cash equivalents
(345)
2,475
Cash and cash equivalents at beginning of year
3,931
1,484
Effect of foreign exchange rate changes
(19)
(28)
Cash and cash equivalents at end of the period
3,567
3,931
CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Issued Share capital
Share Premium
Capital Redemption Reserve
Other Reserve
Non- Controlling Interest
Profit and loss account
Total equity
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Balance at 1 April 2023
1,109
11,729
11,840
(1,450)
-
(18,545)
4,683
Shares Issued (Net of Expenses)
1,994
1,980
-
-
-
3,974
Share based payments
-
-
-
(35)
-
-
(35)
Transactions with owners
1,994
1,980
-
(35)
-
-
(3,939)
Total comprehensive income for the period
-
-
-
-
-
(1,440)
(1,440)
Balance at 31 March 2024
3,103
13,709
11,840
(1,485)
-
(19,985)
7,182
Share based payments
-
-
-
110
-
110
Transactions with owners
-
-
-
110
-
-
110
Adjustment to NCI from foreign entity acquisition
-
-
-
-
99
-
99
Total comprehensive income for the period
-
-
-
-
(5)
6
1
Balance at 31 March 2025
3,103
13,709
11,840
(1,375)
94
(19,979)
7,392
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
1.
Reporting entity
RUA Life Sciences plc ("the Company") is a public limited company and is domiciled and incorporated in Scotland with number SC170071.
The Company is listed on the AIM market of the London Stock Exchange (ticker: RUA, ISIN: GB0033360586)
The registered office is
2 Drummond CrescentIrvineAyrshire
KA11 5AN
These condensed consolidated interim financial statements as at and for the twelve months ended 31 March 2025 comprise the company and its subsidiaries (together referred to as 'the Group'). RUA Life Sciences plc is the ultimate parent company of the Group, whose
principal activities are contract design and manufacture of medical devices and exploiting the value of its IP and know-how.
2.
Basis of preparation
These interim financial statements do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 March 2024 were approved by the Board of Directors on 23 July 2024 and delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified and did not contain statements under sections 498 (2) or (3) of the Companies Act 2006.
As permitted, these interim financial statements have been prepared in accordance with UK AIM Rules and UK-adopted IAS 34, "Interim Financial Reporting". They should be read in conjunction with the annual financial statements for the year ended 31 March 2024, which have been prepared in accordance with UK-adopted international accounting standards, consistent with the IFRS framework adopted in UK law. The accounting policies applied are consistent with those of the annual financial statements for the year ended 31 March 2024, as described in those annual financial statements.
Where new standards or amendments to existing standards have become effective during the year, there has been no material impact on the net assets or results of the Group.
The financial information is presented in pounds Sterling, which is the functional and presentational currency of the Company. Balances are rounded to the nearest thousand (¬£'000) except where otherwise indicated.
These Interim
Financial Statements
were authorised for issue by the Company's Board of Directors on 24 June 2025.
Going concern
The Directors have considered the applicability of the going concern basis in the preparation of the financial statements. This included the review of financial results, internal budgets and cash flow forecasts for the period of at least 12-months following the date of approval of these interim financial statements.
In assessing whether the going concern assumption is appropriate, the directors have considered the Group's existing working capital and are of the opinion that the Group has adequate resources to undertake its planned program of activities for a period of at least 12 months from the date of approval of these financial statements.
Principal Risks and Uncertainties
The principal risks and uncertainties affecting the business activities of the Group remain those detailed on pages 22-24 of the¬†Annual Report 2024, a copy of which is available on the Company's website
www.rualifesciences.com
Profit/(Loss) per share
Profit/(Loss) per share has been calculated on the basis of the result for the period after tax, divided by the weighted average number of ordinary shares in issue in the period of 62,060,272. (31 March 2024: 62,060,272).
3.
BUSINESS SEGMENTS AND REVENUE ANALYSIS
The principal activity of the RUA Life Sciences Group comprises exploiting the value of its IP & know-how, medical device manufacturing and development of cardiovascular devices.
Following the acquisition of the ABISS Group on 6th September 2024 and an internal organisation and reporting review, the Board has decided to rename the business segment formerly known as Contract Manufacturing to Medical Devices and Components to more accurately describe it. This change incorporates revenues generated from contract manufacturing of medical devices, manufacturing and sale & distribution of medical devices into a single reporting segment. This change is consistent with both how the business will be managed and be reported internally in the future.
The following analysis by segment is presented in accordance with IFRS 8 on the basis of those segments whose operating results are regularly reviewed by the Chief Operating Decision Maker (considered to be the Chief Executive Officer) to assess performance and make strategic decisions about the allocation of resources. Segmental results are calculated on an IFRS basis.
A brief description of the segments of the business is as follows:
¬∑
Biomaterials - Licensor of Elast-EonTM polymers to the medical device industry.
¬∑
Medical Devices and Components - End-to-end contract developer, manufacturer, and seller of medical devices and implantable fabric specialist.
¬∑
Vascular - Development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products.
¬∑
Structural Heart - Development of the Group's Elast-Eon composite heart valve material AurTexTM.
Operating results which cannot be allocated to an individual segment are recorded as central and unallocated.
Segment revenue represents revenue from external customers arising from sale of goods and services. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.
The Group's revenue from continuing operations to destinations outside the UK amounted to 100% (year to 31 March 2024: 100%). The revenue analysis below is based on the region of registration of the customer:
The Group's revenue for 12 months to 31 March 2025 is segmented as follows:
Analysis of revenue by income stream
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Biomaterials
Medical Devices & Components
Vascular
Structural Heart
Central and unallocated
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Manufacture and sale of
Medical Devices
-
3,526
-
-
-
3,526
Royalty revenue
587
-
-
-
-
587
Total
587
3,526
-
-
-
4,113
Analysis of revenue by geographical location
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Biomaterials
Medical Devices & Components
Vascular
Structural Heart
Central and unallocated
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Europe
159
524
-
-
-
683
North America
377
2,981
-
-
-
3,358
Middle East
51
-
-
-
-
51
Asia Pacific
0
20
0
0
0
20
Africa
0
1
0
0
0
1
Total
587
3,526
-
-
-
4,113
The Group's revenue for 12 months to 31 March 2024 is segmented as follows:
Analysis of revenue by income stream
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Biomaterials
Medical Devices & Components
Vascular
Structural Heart
Central and unallocated
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Manufacture and sale of
Medical Devices
-
1,679
16
-
-
1,695
Royalty revenue
496
-
-
-
-
496
Total
496
1,679
16
-
-
2,191
Analysis of revenue by geographical location
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Biomaterials
Medical Devices & Components
Vascular
Structural Heart
Central and unallocated
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Europe
158
38
-
-
-
196
North America
288
1,641
16
-
-
1,945
Middle East
50
-
-
-
-
50
Asia Pacific
-
-
-
-
-
-
Africa
-
-
-
-
-
-
Total
496
1,679
16
-
-
2,191
The Group's Segmental analysis for 12 months to 31 March 2025 is segmented as follows:
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Biomaterials
Medical Devices & Components
Vascular
Structural Heart
Central and unallocated
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Consolidated group revenues from external customers
587
3,526
-
-
-
4,113
Contributions to group operating loss
553
166
(672)
(426)
359
(20)
Depreciation
-
267
82
14
3
366
Amortisation of intangible assets
-
47
-
-
8
55
Segment assets
293
4,063
665
114
4,120
9,255
Segment liabilities
6
1,242
233
5
377
1,863
Intangible assets - goodwill
-
301
-
-
-
301
Other intangible assets
-
180
139
-
56
375
Additions to non-current assets
-
38
2
3
19
62
Additions to non-current assets represent capital expenditure incurred by the Group during the reporting period, including purchases of property, plant and equipment, and right-of-use assets arising from new lease arrangements. This excludes any assets or fair value adjustments recognised as part of business combinations, which are reflected within segment assets but not reported as current period additions.
The Group's Segmental analysis for 12 months to 31 March 2024 is segmented as follows:
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Unaudited
Biomaterials
Medical Devices & Components
Vascular
Structural Heart
Central and unallocated
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Consolidated group revenues from external customers
496
1,679
16
-
-
2,191
Contributions to group operating loss
421
931
(1,009)
(465)
(1,815)
(1,937)
Depreciation
-
135
116
17
45
313
Amortisation of intangible assets
-
43
-
-
8
51
Segment assets
225
1,527
1,118
232
5,067
8,169
Segment liabilities
5
218
383
22
359
987
Intangible assets - goodwill
-
301
-
-
-
301
Other intangible assets
-
216
139
-
64
419
Additions to non-current assets
-
14
3
-
38
55
4.
BUSINESS COMBINATIONS
On 6 September 2024, RUA Life Sciences acquired the assets of Analytic Biosurgical Solutions SAS, ("ABISS ") for a cash consideration of ¬£68,000 (‚Ç¨80,000) through a transaction facilitated by the French courts.
ABISS was part of a wider medical devices group which went into insolvent liquidation in¬†June 2021¬†because of the impacts of Covid. Although the parent company was in liquidation, ABISS itself was not placed in receivership/liquidation. ABISS has continued to trade solvently and has traded within its own financial resources.
There is no future, deferred or contingent consideration due on this transaction. Further details of the acquisition are detailed in the Chairmans statement.
As part of the acquisition, the net identifiable assets' carrying value was determined to be ¬£985,000, which exceeds the total consideration transferred of ¬£68,000. Consequently, a gain on a bargain purchase of ¬£917,000 has been recognised in profit or loss as of the acquisition date.
This gain reflects the favourable terms of the transaction, arising primarily from the purchase through court proceedings at a value significantly below the fair value of the assets acquired.
The Group intends to complete the review of the fair value of the acquired assets and liabilities during
the annual reporting process for the 18-month period ending 30 September 2025
, as permitted under IFRS 3-Business Combinations. Thus,
the accounting is currently provisional
.
Details of the Acquisition:
¬∑
Date of Acquisition: 6 September 2024
¬∑
Consideration Transferred: ¬£
68,000
¬∑
Carrying Value of Identifiable Net Assets Acquired:
¬£985,000
¬∑
Gain on Bargain Purchase:
¬£917,000
¬∑
Recognition of Gain: Included under "Other Income" in the Statement of Comprehensive Income for the period ended
31 March 2025
The Group continues to assess the fair value of assets and liabilities acquired in the ABISS transaction. As of 31 March 2025, these amounts remain provisional and may be subject to further adjustment as permitted under IFRS 3 during the measurement period. The updated provisional fair values at 31 March 2025 are as follows
.
Details of the consideration paid and the fair value of net assets acquired are as follows:
ABISS Group
Provisionally recognised fair value on acquisition
GB¬£000
Consideration paid
68
Less:
Intangible Assets
11
Property, Plant and Equipment
1,015
Trade receivables
275
Inventory
322
WIP
322
Other Current Assets
107
Cash
170
Trade payables
(106)
Other Current Liabilities
(196)
Other interest-bearing loans and borrowings
(836)
Non-Controlling Interest
(99)
Carrying value of net assets acquired
985
Gain on bargain purchase
917
5.
GOODWILL
The final valuation following the acquisition of RUA Medical Devices Limited gave rise to adjustments being required to the value of intangibles recognised in the Interim Report for the six months ended 30 September 2020, and lead to the following goodwill being recognised:
No impairment review has been carried out in the six-month period.
GB¬£000
Gross carrying amount
Balance at 31 March 2024
301
Balance at
31 March 2025
301
6.
OTHER INTANGIBLE ASSETS
Development costs
Intellectual property
Customer Related
Technology Based
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Gross carrying amount
At 31 March 2023
337
3,325
247
141
4,050
Additions
-
-
-
-
-
At 31 March 2024
337
3,325
247
141
4,050
Additions
391
5
-
6
402
At 31 March 2025
728
3,330
247
147
4,452
Amortisation and impairment
At 31 March 2023
337
3,114
87
42
3,580
Amortisation
-
8
29
14
51
At 31 March 2024
337
3,122
116
56
3,631
Amortisation
-
12
29
14
55
Impairment
391
-
-
-
391
At 31 March 2025
728
3,134
145
70
4,077
Net book value
At 31 March 2023
-
211
160
99
470
At 31 March 2024
-
203
131
85
419
At 31 March 2025
-
196
102
77
375
As part of the acquisition of Analytic Biosurgical Solutions SAS ("ABISS") on 6 September 2024, the Group recognised identifiable intangible assets with a carrying value of ¬£391,000. These assets primarily related to previously capitalised research and development expenditure.
During the measurement period permitted under IFRS 3, management conducted a detailed review of the acquired intangible assets as part of the purchase price allocation process. It was determined that the assets did not possess standalone commercial value. As a result, the full amount was impaired retrospectively in the financial statements, with no residual net book value at the reporting date.
7.
PROPERTY, PLANT AND EQUIPMENT
Land & Buildings
Assets Under Construction
Plant & Machinery
Office Equipment
Motor Vehicles
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Cost
At 31 March 2023
1,335
142
1,905
95
25
3,502
Additions
-
-
18
4
33
55
Transfer of Assets
-
(142)
142
-
-
-
Disposals
-
-
-
-
(25)
(25)
At 31 March 2024
1,335
-
2,065
99
33
3,532
Additions
657
-
393
7
20
1,077
Disposals
-
-
(1)
-
-
(1)
At 31 March 2025
1,992
-
2,457
106
53
4,608
Depreciation
At 31 March 2023
180
-
509
50
24
763
Charge
53
-
236
15
9
313
At 31 March 2024
233
-
745
65
33
1,076
Charge
91
-
258
14
3
366
At 30 31 March 2025
324
-
1,003
79
36
1,442
Net book value
At 31 March 2023
1,155
142
1,396
45
1
2,739
At 31 March 2024
1,102
-
1,320
34
-
2,456
At 31 March 2025
1,668
-
1,454
27
17
3,166
Included in the net carrying amount of property plant and equipment are right-of-use assets as follows:
Buildings (Leased)
Plant & Machinery (Leased)
Motor Vehicles (Leased)
Total
GB¬£000
GB¬£000
GB¬£000
GB¬£000
Cost
At 31 March 2023
-
391
25
416
Additions
-
33
33
Disposals
-
-
(25)
(25)
At 31 March 2024
-
391
33
424
Additions
656
8
19
683
At 31 March 2025
656
399
52
1,107
Depreciation
At 31 March 2023
-
48
24
72
Charge
-
30
9
39
At 31 March 2024
-
78
33
111
Charge
50
28
3
81
At 31 March 2025
50
106
36
192
Net book value
At 31 March 2023
-
343
1
344
At 31 March 2024
-
313
-
313
At
31 March 2025
606
293
16
915
8.
INVENTORIES
Inventories consist of the following:
Unaudited
Audited
Twelve months to 31 Mar 2025
Twelve months to 31 Mar 2024
GB¬£000
GB¬£000
Raw Materials
215
59
Work in Progress
372
53
Finished Goods
167
-
754
112
The cost of inventories recognised as an expense and included in cost of goods sold amounted to ¬£212k (2024: ¬£36k).
9. TRADE AND OTHER RECEIVABLES
Unaudited
Audited
Twelve months to 31 Mar 2025
Twelve months to 31 Mar 2024
GB¬£000
GB¬£000
Current:
Trade receivables - gross
519
301
Allowance for credit losses
-
-
Trade receivables net
519
301
Tax credit due
-
189
Prepayments and accrued income
573
460
1,092
950
10.
CASH AND CASH EQUIVALENTS
Unaudited
Audited
Twelve months to 31 Mar 2025
Twelve months to 31 Mar 2024
GB¬£000
GB¬£000
Cash at bank and in hand
3,567
3,931
3,567
3,931
11. BORROWINGS & LEASE LIABILITIES
Unaudited
Audited
Twelve months to 31 Mar 2025
Twelve months to 31 Mar 2024
GB¬£000
GB¬£000
Current:
Bank Loans
234
31
Lease Liabilities
156
86
390
117
Non-current:
Bank loans
19
132
Lease Liabilities
620
140
639
272
Total Borrowings & Lease Liabilities
1,029
389
Bank loans
Lease liabilities
Total
GB¬£000
GBP¬£000
GB¬£000
Repayable in less than 6 months
176
85
261
Repayable in 7 to 12 months
58
71
129
Repayable in 1 to 5 years
19
439
458
Repayable after 5 years
-
181
181
253
776
1,029
¬£117,519 of bank loans is secured on the property at 2 Drummond Crescent, Irvine, Ayrshire and subject to a bond and floating charge over the Group's assets. Secured bank loans carry a variable rate of interest, which were between 6% and 7.8%.
¬£14,787 of bank loans is an unsecured UK government support loan. Unsecured bank loans carry an effective rate of interest at 9%.
¬£121,171 of bank loans is an unsecured French government support loan. Unsecured bank loans carry an effective rate of interest at 6%.
The lease liabilities are secured by the related underlying assets. Lease borrowings carry fixed rates of interest, ranging between 4.0% and 9.6%.
Reconciliation of change in lease liabilities:
GB¬£000
As at 1 April 2023
282
Payment of lease liability - principal
(58)
Payment of lease liability - interest
(41)
Interest expense
41
Additions
2
Disposals
-
As at 31 March 2024
226
Payment of lease liability - principal
(132)
Payment of lease liability - interest
(39)
Interest expense
39
Additions
682
Disposals
-
As at 31 March 2025
776
12. TRADE AND OTHER PAYABLES
Unaudited
Audited
Twelve months to 31 Mar 2025
Twelve months to 31 Mar 2024
GB¬£000
GB¬£000
Current liabilities:
Trade payables
110
140
Other payables
180
46
Accruals and deferred income
393
222
683
408
Other Liabilities (Grant Income)
87
116
Total Trade and Other Payables
770
524
Deferred grant income is included within other liabilities in the Consolidated Statement of Financial Position. ¬£29,000 (2024: ¬£29,000) is included in current liabilities and ¬£58,000 (2024: ¬£87,000) is included in Non-current Liabilities.
13. SUBSEQUENT EVENTS
None to report.
14.
ISSUED SHARE CAPITAL
The Company's issued share capital as at 31 March 2025 comprises 62,060,272 Ordinary Shares of which none are held in treasury.
15. INTERIM ANNOUNCEMENT
The interim results announcement was released on 25 June 2025. A copy of this Interim Report is also available on the Company's website www.rualifesciencs.com.
CORPORATE INFORMATION AND ADVISERS
HEAD OFFICE
2 Drummond Crescent
Irvine
Ayrshire
KA11 5AN
REGISTERED OFFICE
2 Drummond Crescent
Irvine
Ayrshire
KA11 5AN
web: www.rualifesciences.com
email: info@rualifesciences.com
NOMINATED ADVISER AND BROKER
REGISTRARS
Cavendish Capital Markets Limited
Equiniti Limited
One Bartholomew Close
Aspect House
London
Spencer Road
EC1A 7BL
West Sussex
BN99 6DA
LAWYERS
Burness Paull LLP
50 Lothian Road
Festival Square
Edinburgh
EH3 9WJ
INDEPENDENT AUDITOR
RSM Audit UK LLP
Centenary House
69 Wellington Street
Glasgow
G2 6HG
Registered in Scotland, Company No.SC170071
Financial statements will be available to Shareholders from the Company Website, along with copies of the announcement. Dealings permitted on Alternative Investment Market (AIM) of the London¬†Stock Exchange
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
IR PKQBPCBKDBAB
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üèõÔ∏è</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Director/PDMR Shareholding</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">HOLDINGS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Major holder disclosure - routine regulatory filing.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">6th May 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">9:30 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">The Group</td>
                    </tr>
                    
                        <tr style="border-bottom: 1px solid #e2e8f0;">
                            <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">ACTION:</td>
                            <td style="padding: 8px; font-weight: 600; font-size: 12px; color: #3b82f6;">PURCHASE</td>
                        </tr>
                        
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
6 May 2025 09:30
RNS Number : 4837H
RUA Life Sciences PLC
06 May 2025
6 May 2025
RUA Life Sciences Plc
("
RUA Life Sciences
", the "
Company
" or the "
Group
")
Director/PDMR Shareholding
RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon‚Ñ¢), announces that it has been notified that Lachlan Smith, Chief Financial Officer of the Company, on 2 May 2025, purchased 20,228 ordinary shares in the Company at 11.86 pence per ordinary share.
Following this purchase, Lachlan Smith is interested in 130,508 ordinary shares in the Company, representing approximately 0.21 per cent. of the Company's issued ordinary share capital.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Lachlan Smith
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
RUA Life Sciences plc
b)
LEI
213800BMVB22PVOJ9Z28
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Transaction
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 5 pence each
ISIN: GB0033360586
b)
Nature of the transaction
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
11.86 pence
20,228
d)
Aggregated information
- Aggregated volume
- Price
N/A (Single transaction)
e)
Date of the transaction
2 May 2025
f)
Place of the transaction
London Stock Exchange, AIM
- Ends -
For further information contact:
RUA Life Sciences
Bill Brown, CEO
Lachlan Smith, CFO
Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073
Cavendish¬†Capital Markets Limited
(Nominated Adviser and Broker)
Giles Balleny/Dan Hodkinson¬†(Corporate Finance)
Charlie Combe¬†(Broking)
Michael Johnson¬†(Sales)
Tel: +44 (0)20 7220 0500
About¬†RUA Life Sciences
The¬†RUA Life Sciences¬†group was created in¬†April 2020¬†when¬†RUA Life Sciences Plc¬†(formerly known as¬†AorTech International Plc) acquired¬†RUA Medical Devices Limited¬†to create a fully formed medical device business.¬†RUA Life Sciences¬†is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon
TM
, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon
TM
, manufacturing a device or component, or developing next generation medical devices, a¬†RUA Life Sciences¬†business is pursuing our vision.
Elast-Eon‚Ñ¢'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Contract Manufacture:
End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials:
Licensor of Elast-Eon
TM
polymers to the medical device industry.
RUA Vascular:
Commercialisation of open surgical vascular grafts and patches
RUA Structural Heart:
Development of polymeric leaflet systems for heart valves.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
DSHSSLSAMEISEFI
                </div>
            </details>
            
            </div>
            
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-02-11 ‚Ä¢ CrashDash APEX Engine (Advanced Pattern EXploration)<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
            <div style="margin-top: 12px; padding-top: 12px; border-top: 1px solid #e5e7eb; font-size: 11px; color: #999; line-height: 1.5;">
                <strong>APEX</strong> is a CrashDash AI-powered quantitative intelligence platform that analyzes multi-source market signals using advanced pattern recognition. Designed for professional traders and institutional users, it synthesizes technical, sentiment, and fundamental data into actionable market profiles‚Äîready for seamless integration into workflows.
            </div>
        </div>

    </div>
</body>
</html>